Total Equity
Pfizer Total Equity increased by 4.2% to $90.10B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 0.3%, from $90.34B to $90.10B. Over 5 years (FY 2020 to FY 2025), Total Equity shows an upward trend with a 6.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
A growing equity base generally signals strong financial health and value creation, whereas a shrinking base may indicate significant losses or heavy share buybacks.
Detailed definition
This represents the residual interest in the assets of the company after deducting all liabilities, effectively serving...
Peer comparison
Stable, mature pharmaceutical companies typically maintain a robust equity base to support long-term R&D and dividend commitments.
total_stockholders_equityHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $70.04B | $75.69B | $77.20B | $82.42B | $87.21B | $92.63B | $95.66B | $100.97B | $99.02B | $96.93B | $89.01B | $92.28B | $87.70B | $92.29B | $88.20B | $90.34B | $88.70B | $92.80B | $86.48B | $90.10B |
| QoQ Change | — | +8.1% | +2.0% | +6.8% | +5.8% | +6.2% | +3.3% | +5.5% | -1.9% | -2.1% | -8.2% | +3.7% | -5.0% | +5.2% | -4.4% | +2.4% | -1.8% | +4.6% | -6.8% | +4.2% |
| YoY Change | — | — | — | — | +24.5% | +22.4% | +23.9% | +22.5% | +13.5% | +4.6% | -6.9% | -8.6% | -11.4% | -4.8% | -0.9% | -2.1% | +1.1% | +0.6% | -2.0% | -0.3% |
Total Equity at Other Companies
Frequently Asked Questions
- What is Pfizer's total equity?
- Pfizer (PFE) reported total equity of $90.10B in Q1 2026.
- How has Pfizer's total equity changed year-over-year?
- Pfizer's total equity decreased by 0.3% year-over-year, from $90.34B to $90.10B.
- What is the long-term trend for Pfizer's total equity?
- Over 5 years (2020 to 2025), Pfizer's total equity has grown at a 6.5% compound annual growth rate (CAGR), from $63.24B to $86.48B.
- What does total equity mean?
- The total value of the company that belongs to its shareholders after all debts are paid.